Literature DB >> 15557341

Analysis of SHP-1-mediated down-regulation of the TRK-T3 oncoprotein identifies Trk-fused gene (TFG) as a novel SHP-1-interacting protein.

Emanuela Roccato1, Claudia Miranda, Giovanna Raho, Sonia Pagliardini, Marco A Pierotti, Angela Greco.   

Abstract

SHP-1 is a cytoplasmic SH2 domain containing protein-tyrosine phosphatase (PTP) involved in the negative regulation of multiple signaling pathways in hematopoietic, nervous, and epithelial cells. The thyroid TRK-T3 oncogene consists of the NTRK1 tyrosine kinase domain fused in-frame with sequences of the TFG (TRK-fused gene), encoding a protein of unknown function. TFG contains a coiled-coil domain responsible for TRK-T3 oligomerization. In addition, recent analysis of the sequences outside of the coiled-coil domain suggested possible interactions with other proteins. Based on the presence of a putative SHP-1 SH2-binding site within the TFG sequences, we have investigated the role of the SHP-1 phosphatase in TRK-T3 oncoprotein signaling. In this study we show that SHP-1 interacts with and down-regulates TRK-T3. We provide evidence that SHP-1 SH2 and catalytic domains, respectively, associate with the TFG- and NTRK1-derived portions of TRK-T3. Our data contribute to the definition of cellular mechanisms involved in thyroid tumorigenesis. Moreover, it reveals TFG as a novel protein able to modulate SHP-1 activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557341     DOI: 10.1074/jbc.M407522200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Mechanisms of activation and repression by the alternative splicing factors RBFOX1/2.

Authors:  Shuying Sun; Zuo Zhang; Oliver Fregoso; Adrian R Krainer
Journal:  RNA       Date:  2011-12-19       Impact factor: 4.942

2.  A novel model to identify interaction partners of the PTEN tumor suppressor gene in human bladder cancer.

Authors:  Mikael Herlevsen; Gary Oxford; Celeste Ptak; Jeffrey Shabanowitz; Donald F Hunt; Mark Conaway; Dan Theodorescu
Journal:  Biochem Biophys Res Commun       Date:  2006-11-21       Impact factor: 3.575

Review 3.  Novel approaches in anaplastic thyroid cancer therapy.

Authors:  Kun-Tai Hsu; Xiao-Min Yu; Anjon W Audhya; Juan C Jaume; Ricardo V Lloyd; Shigeki Miyamoto; Tomas A Prolla; Herbert Chen
Journal:  Oncologist       Date:  2014-09-26

4.  The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.

Authors:  Samar A Hegazy; Peng Wang; Mona Anand; Robert J Ingham; Pascal Gelebart; Raymond Lai
Journal:  J Biol Chem       Date:  2010-04-27       Impact factor: 5.157

5.  Role of STAT3 in in vitro transformation triggered by TRK oncogenes.

Authors:  Claudia Miranda; Tiziana Fumagalli; Maria Chiara Anania; Maria Grazia Vizioli; Sonia Pagliardini; Marco A Pierotti; Angela Greco
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

6.  ced-4 and proto-oncogene tfg-1 antagonistically regulate cell size and apoptosis in C. elegans.

Authors:  Ling Chen; Tom McCloskey; Pradeep M Joshi; Joel H Rothman
Journal:  Curr Biol       Date:  2008-07-22       Impact factor: 10.834

7.  Immunohistochemical Mapping of TRK-Fused Gene Products in the Rat Brainstem.

Authors:  Shigeko Takeuchi; Chiaki Masuda; Hisae Maebayashi; Ikuo Tooyama
Journal:  Acta Histochem Cytochem       Date:  2012-02-11       Impact factor: 1.938

8.  Expression and Localization of TRK-Fused Gene Products in the Rat Brain and Retina.

Authors:  Hisae Maebayashi; Shigako Takeuchi; Chiaki Masuda; Satoshi Makino; Kenji Fukui; Hiroshi Kimura; Ikuo Tooyama
Journal:  Acta Histochem Cytochem       Date:  2011-12-13       Impact factor: 1.938

9.  Immunohistochemical Localization of an Isoform of TRK-Fused Gene-Like Protein in the Rat Retina.

Authors:  Chiaki Masuda; Shigeko Takeuchi; Naomi J Bisem; Steven R Vincent; Ikuo Tooyama
Journal:  Acta Histochem Cytochem       Date:  2014-04-25       Impact factor: 1.938

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.